Literature DB >> 6970344

CT studies before and after CNS treatment for acute lymphoblastic leukemia and malignant non-hodgkin's lymphoma in childhood.

K Kretzschmar, P Gutjahr, J Kutzner.   

Abstract

CT was performed on 72 children with acute lymphoblastic leukemia or non-Hodgkin's lymphoma. Thirty-two of these patients were investigated prior to CNS radiation and intrathecal methotrexate therapy. Ten of these patients (31%) were known to have hydrocephalic dilatation of the CSF spaces. Clinical data and subsequent observations with analysis of the CT findings show that no difference in the attenuation values of brain tissue occurs in the absence of a CNS relapse. The percentage of abnormal findings before and after therapy remains constant. The adverse late effect described in the CT literature seem principally to be damage diagnosed too late. It is questionable if the CT demonstration of dilated CSF spaces before treatment has a prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6970344     DOI: 10.1007/BF00336678

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  61 in total

Review 1.  Neurotoxicity of commonly used antineoplastic agents (first of two parts).

Authors:  H D Weiss; M D Walker; P H Wiernik
Journal:  N Engl J Med       Date:  1974-07-11       Impact factor: 91.245

Review 2.  Paraplegia following intrathecal chemotherapy.

Authors:  J H Saiki; S Thompson; F Smith; R Atkinson
Journal:  Cancer       Date:  1972-02       Impact factor: 6.860

3.  Proceedings: Parenchymatous degeneration of the central nervous system in childhood leukemia.

Authors:  B Hendin; D C DeVivo; R Torack; M E Lell; A H Ragab; T J Vietti
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

4.  The central nervous system in childhood leukemia. I. The arachnoid.

Authors:  R A Price; W W Johnson
Journal:  Cancer       Date:  1973-03       Impact factor: 6.860

5.  Comparison of two methods of preventing central nervous system leukemia.

Authors:  R J Aur; H O Hustu; M S Verzosa; A Wood; J V Simone
Journal:  Blood       Date:  1973-09       Impact factor: 22.113

6.  Cranial computed tomography in leukaemia.

Authors:  D P Kingsley; B E Kendall
Journal:  Neuroradiology       Date:  1978       Impact factor: 2.804

7.  [Unusual CT skull findings after preventive CNS treatment of acute leukemia in children].

Authors:  J Treuner; K H Hübener; H Bömer; U Küpper
Journal:  Onkologie       Date:  1979-04

8.  Effects of chemotherapy on the central nervous system. A study of parenteral methotrexate in long-term survivors of leukemia and lymphoma in childhood.

Authors:  A T Meadows; A E Evans
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

9.  Childhood acute lymphocytic leukemia: study VIII.

Authors:  R J Aur; J V Simone; M S Verzosa; H O Hustu; L F Barker; D P Pinkel; G Rivera; G V Dahl; A Wood; S Stagner; C Mason
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

10.  [Combination chemotherapy and cranial irradiation in 530 children with acute lymphoblastic leukaemia (author's transl)].

Authors:  F Lampert
Journal:  Dtsch Med Wochenschr       Date:  1977-06-24       Impact factor: 0.628

View more
  3 in total

1.  Computed tomography of the brain following prophylactic treatment with irradiation therapy and intraspinal methotrexate in children with acute lymphoblastic leukemia.

Authors:  E Lund; B Hamborg-Pedersen
Journal:  Neuroradiology       Date:  1984       Impact factor: 2.804

2.  The development of cerebral CT changes during treatment of acute lymphocytic leukemia in childhood.

Authors:  H Pedersen; N Clausen
Journal:  Neuroradiology       Date:  1981       Impact factor: 2.804

3.  Cranial MRI in Childhood Acute Leukemia during Treatment and Follow-Up Including the Impact of Intrathecal MTX-A Single-Center Study and Review of the Literature.

Authors:  Marvin Mergen; Sascha Scheid; Hannah Schubmehl; Martin Backens; Wolfgang Reith; Norbert Graf
Journal:  Cancers (Basel)       Date:  2022-09-26       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.